An open, multicentre, randomised parallel group clinical study to compare safety and efficacy of tacrolimus (FK506) with monoclonal anti-IL2R antibodies (daclizumab) vs tacrolimus (FK506) with steroids and evaluate pharmacokinetics in liver allograft recipients receiving suboptimal livers

Trial Profile

An open, multicentre, randomised parallel group clinical study to compare safety and efficacy of tacrolimus (FK506) with monoclonal anti-IL2R antibodies (daclizumab) vs tacrolimus (FK506) with steroids and evaluate pharmacokinetics in liver allograft recipients receiving suboptimal livers

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Oct 2014

At a glance

  • Drugs Tacrolimus (Primary) ; Corticosteroids; Daclizumab
  • Indications Liver transplant rejection
  • Focus Registrational; Therapeutic Use
  • Acronyms PANTERA
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 07 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top